Abstract
Over the last 20 years there has been a debate about the best model of screening for aneuploidies: to simplify, the alternatives are a combined test in the first trimester or an integrated test using biochemical parameters over the first and second trimesters. The inclusion of objective measurements of risks of pregnancy pathologies in the algorithm of first-trimester screening was immense progress, as well as an argument for the predominant use of this examination: this meant that detection of preg - nancy risks and fetus morphology (premature delivery, preeclampsia, intrauterine growth retardation) as early as at the end of the first trimester came to the fore, so detection of aneuploidies was thus no longer the most significant outcome of this test.
Now we are witnessing the dynamic onset of a new method,